Lupin Pharmaceuticals has received final approval for its abbreviated new drug application for divalproex sodium delayed-release tablets, 125mg, 250mg and 500mg from the FDA. Commercial shipments of the product have already commenced.

Lupin Pharmaceuticals has received tentative approval from the FDA for the company's abbreviated new drug application for Escitalopram oxalate tablets 10mg and 20mg.

Lupin Pharmaceuticals has announced that the FDA has granted final approval for its abbreviated new drug application for Ramipril capsules, 1.25mg. 2.5mg, 5mg and 10mg. Commercial shipments of the product have commenced.

Lupin Pharmaceuticals has received tentative approval for the company's abbreviated new drug application for Topiramate tablets, 25mg, 50mg, 100mg and 200mg from the FDA.

Lupin Pharmaceuticals has been cleared by the FDA to market the generic equivalent of Merck & Co.'s high cholesterol treatment Zocor, in 10mg, 20mg, 40mg and 80mg strengths.